State Street Corp Has $19.65 Million Position in Omeros Corporation (OMER)
State Street Corp raised its holdings in Omeros Corporation (NASDAQ:OMER) by 7.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 987,057 shares of the biopharmaceutical company’s stock after purchasing an additional 66,827 shares during the quarter. State Street Corp owned 2.20% of Omeros Corporation worth $19,652,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. Ingalls & Snyder LLC raised its position in Omeros Corporation by 1.0% in the second quarter. Ingalls & Snyder LLC now owns 5,143,289 shares of the biopharmaceutical company’s stock valued at $102,377,000 after purchasing an additional 50,970 shares during the period. Vanguard Group Inc. raised its position in Omeros Corporation by 5.4% in the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock valued at $36,341,000 after purchasing an additional 94,280 shares during the period. Northern Trust Corp raised its position in Omeros Corporation by 6.4% in the second quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock valued at $11,397,000 after purchasing an additional 34,328 shares during the period. Stifel Financial Corp raised its position in Omeros Corporation by 54.1% in the second quarter. Stifel Financial Corp now owns 356,160 shares of the biopharmaceutical company’s stock valued at $7,091,000 after purchasing an additional 125,110 shares during the period. Finally, Geode Capital Management LLC raised its position in Omeros Corporation by 10.7% in the first quarter. Geode Capital Management LLC now owns 327,730 shares of the biopharmaceutical company’s stock valued at $4,955,000 after purchasing an additional 31,644 shares during the period. Institutional investors own 45.37% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “State Street Corp Has $19.65 Million Position in Omeros Corporation (OMER)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/state-street-corp-has-19-65-million-position-in-omeros-corporation-omer/1711302.html.
A number of equities research analysts have commented on OMER shares. Maxim Group set a $24.00 target price on Omeros Corporation and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Wedbush restated an “outperform” rating and issued a $47.00 target price on shares of Omeros Corporation in a research report on Friday, August 18th. Cantor Fitzgerald restated a “hold” rating and issued a $19.00 target price (up previously from $15.00) on shares of Omeros Corporation in a research report on Thursday, August 24th. Zacks Investment Research upgraded Omeros Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a research report on Thursday, October 19th. Finally, Cowen and Company downgraded Omeros Corporation from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $34.14.
Shares of Omeros Corporation (NASDAQ:OMER) opened at $19.81 on Friday. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. Omeros Corporation has a 1-year low of $8.71 and a 1-year high of $27.09.
Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. Omeros Corporation’s quarterly revenue was up 91.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.34) EPS. sell-side analysts anticipate that Omeros Corporation will post -1.07 EPS for the current year.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.